Aurinia Pharmaceuticals (AUPH) Reports FDA Approval of LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
Go back to Aurinia Pharmaceuticals (AUPH) Reports FDA Approval of LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis| Hauppauge Digital, Inc. (NASDAQ: AUP) | Delayed: 0.47 +0.23 (95.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.24 | 52 Week High | $0.67 | |||
| Open | $0.25 | 52 Week Low | $0.25 | |||
| Day High | $0.67 | P/E | 0.87 | |||
| Day Low | $0.25 | EPS | $0.54 | |||
| Volume | 9,138 | |||||
| (NASDAQ: AUPH) | Delayed: 5.03 -0.06 (1.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.09 | 52 Week High | $5.69 | |||
| Open | $5.09 | 52 Week Low | $1.42 | |||
| Day High | $5.16 | P/E | N/A | |||
| Day Low | $5.00 | EPS | $0.00 | |||
| Volume | 785,988 | |||||
